About: Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $21.28 (-0.47%)
MLYS NASDAQ Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc. Common Stock share price
Atividade de preço de MLYS
Último preço
$ 21,380
Variação (24h)
0,25 USD (1,18%)
Volume
1.53M
Volume (média 4 sem.)
-
Abertura
$ 21,13
Variação do dia
$ 20,92 - $ 22,15
Fechamento anterior
$ 21,13
Último negócio
28 Oct, 8:00 pm GMT+0
Atrasado
28 Oct, 8:00 pm GMT+0
MLYS price performance
Atrasado
28 Oct, 8:00 pm GMT+0
quote.marketSignals